Publications


Min Thura, Abdul Qader Omer Al-Aidaroos, Wei Peng Yong, Koji Kono, Abhishek Gupta, You Bin Lin, Kousaku Mimura, Jean Paul Thiery, Boon Cher Goh, Patrick Tan, Ross Soo, Cheng William Hong, Lingzhi Wang, Suling Joyce Lin, Elya Chen, Sun Young Rha, Hyun Cheol Chung, Jie Li, Sayantani Nandi, Hiu Fung Yuen, Shu-Dong Zhang, Yeoh Khay Guan, Jimmy So and Qi Zeng *JCI Insight* 1(9):e87607. doi:10.1172/jci.insight.87607


Zu Ye, Abdul Qader Omer Al-aidaroos, Jung Eun Park, Hiu Fung Yuen, Shu Dong Zhang, Abhishek Gupta, Youbin Lin, Han-Ming Shen and Qi Zeng (2015) *Scientific Reports*, 5:17046 | DOI: 10.1038/srep17046


*equal first authors


PRL-3 induces EGFR activation and addiction in human cancer cells.  
*Journal of Clinical Investigation* 123:3459-3471

PRL-3 suppresses c-Fos and integrin α2 expression in ovarian cancer cells.  

The RNase III enzyme Dicer is essential for germinal center B-cell formation.  
*Blood* 119:767-76.

Guo, K.*, Tang, J.P.*, Jie, L.*, Al-Aidaroos, A.Q., Hong, C.W., Tan, C.P., Park, J.E.,  
First Chimeric Antibody in Targeting Intracellular Oncoprotein for Cancer Therapy in Mice.  
* equal first authors

Huang, C., Zeng, Q. (2011) Targeting Intracellular Oncoproteins with Antibody Therapy or  
Vaccination.  
*Science Translational Medicine* 3(99):99ra85. (Proposed the new concept of  
unconventional Immunotherapies to target intracellular oncoproteins)  
* equal first authors

(2011)  
Phosphatase PRL-3 is a Direct Regulatory Target of TGFβ in Colon Cancer Metastasis.  
*Cancer Research* 71:234-44.

PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and  
implicated in anti-AML therapy.  
*PLoS One.* 12:6(5)

Wang, H., Vardy, L., Tan, C.P., Loo, J.M., Guo, K., Li, J., Lim, S.G., Zhou, J., Chng, W.J.,  
Ng, S.B., Li, H.X., and Zeng, Q. (2010)  
PCBP1 Suppresses the Translation of Metastasis-Associated PRL-3 Phosphatase.  
*Cancer Cell* 18:52-62.


*Clinical Cancer Research* 11:2195-2204 (Cover).


*Cancer Biology & Therapy* 3:945-951 (Cover with commentary).

* equal first authors


*Cancer Research* 63:2716-2722 (*Correspondence*).


**Invited reviews:**

FEBS Lett, Invited review

Hong, C.W. and Zeng Q. (2012)
Awaiting a New Era of Cancer Immunotherapy.

Al-Aidaroos, A.Q., and Zeng, Q. (2010)
PRL-3 phosphatase and human cancers.
* Journal of Cellular Biochemistry * 111:1087-98 (Highlighted as Cover).

The emerging role of the Hippo pathway in cell contact inhibition, organ size control and cancer development in mammals (mini-review).